"The Trump Administration’s latest proposal to lower drug prices is catastrophic for our most vulnerable seniors, especially the patient communities that don’t yet have a single therapy for their disease. It is also an attack on Massachusetts’ life sciences companies who are developing the next wave of breakthrough therapies, a majority of which will be treatments covered under Medicare Part B. Cutting edge science is happening here and across the US because government has laid clear the incentives necessary for that science to leave the lab and reach patients who need and deserve it. Their proposed reforms fly in the face of that agreement."
– Robert K. Coughlin, MassBio President & CEO